word count: 247 12 Text word count: 5,657 Abstract 15 Influenza viruses and rhinoviruses are responsible for a large number of acute respiratory 16 viral infections in human populations and are detected as co-pathogens within hosts. Clinical and 17
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clinical signs ( Fig. 1I ) compared to mock/PR8 Hi -infected mice. In summary, RV lessened the 142 severity of a mild or moderate, but not severe, infection by PR8 when inoculated two days before 143 PR8.
145
Co-infection by RV leads to more rapid clearance of PR8 from the lungs 146 The above experiments established that RV effectively attenuated disease due to a mild 147 PR8 infection. We next asked whether the reduced virulence during co-infection was due to 148 inhibition of PR8 replication within the lungs. Groups of mice were either mock-inoculated or 149 inoculated with RV two days before inoculating with a low dose of PR8 (Mock/PR8, RV/PR8). 150 Groups of mice were euthanized on days 4, 7, and 10 after PR8 inoculation and lungs were 151 harvested for PR8 quantification. On day 4 after PR8 inoculation, the viral loads in single virus 152 and co-infected mice were not significantly different, but co-infected mice had greater variation 153 within the group (Fig. 2) . However, on day 7, the Mock/PR8-infected mice still had PR8 titers in 154 the 10 4 -10 5 range, whereas the RV/PR8-co-infected mice had undetectable levels of PR8. By day 155 10, both groups had undetectable levels of infectious PR8. This suggests that co-infection with 156 RV did not prevent infection or inhibit early replication of PR8, but induced more rapid 157 clearance of PR8 from the lungs. 158 We also evaluated lung sections for PR8 antigens by immunohistochemistry. The lack of 159 PR8 antigen staining in lung sections from mock-inoculated mice confirmed the specificity of 160 staining (Fig. 3A) . On day 4, both single-and co-infected groups had extensive infection of the 161 bronchial epithelium (not shown) in addition to viral antigen in bronchiolar epithelium and 162 alveoli (Fig. 3B ). The Mock/PR8-infected lung tissues had more extensive sloughing of infected 163 8 epithelia with viral antigens associated with mucopurulent material in the airways. While 164 Mock/PR8-infected animals had clear progression of infection from upper and lower airways 165 into the adjacent alveoli, co-infected animals appeared to have viral antigen in the alveoli earlier 166 and it was not always associated with infection of bronchiolar epithelium in the same region. 167 Both groups had extensive viral antigen staining in the alveoli, with antigen detected in 168 pneumocytes and immune cells, especially macrophages and neutrophils. On day 7, antigen 169 staining was reduced in lung tissues from both groups and was localized in airways, especially 170 cells that had been sloughed from the epithelium (Fig. 3C ). PR8 antigens in the alveoli were 171 mainly found in immune cells by day 7, suggesting clearance of infection. In agreement with the 172 undetectable levels of infectious PR8, both groups had little antigen staining on day 10, which 173 was predominantly in immune cells within focal areas (not shown). These findings support our 174 observation that co-infection by RV did not completely inhibit replication of PR8 in the 175 respiratory tract. 178 Next, we used a murine lung epithelial cell line (LA-4) that is susceptible to infection by 179 both viruses (30) to determine if co-infection by RV would interfere with PR8 replication in vitro.
RV does not interfere with replication of PR8 in vitro

180
LA-4 cells were inoculated with RV 6 or 12 hours before or simultaneously with PR8. PR8 181 released into the media was quantified by TCID 50 assay in MDCK cells. We confirmed that the 182 presence of RV in these samples did not interfere with quantification of PR8 in MDCK cells (not 183 shown). There were no significant differences at any time point between cells inoculated with 184 PR8 alone or co-infected with RV either simultaneously with or 12 hours before PR8 ( Fig. 4A , 185 C). There were significant differences at 24 and 96 hours when cells were inoculated with RV 6 186 9 hours before PR8 (Fig. 4B ). The lower PR8 titers at 96 hours may have been due to higher cell 187 death from two viruses being present, providing fewer susceptible cells for PR8 replication.
188
Though not significant, this trend was also seen when cells were inoculated with both viruses 189 simultaneously (Fig. 4A ). These data help corroborate our in vivo finding that RV did not inhibit 190 replication of PR8. Rather, co-infection is most likely stimulating the immune system, leading to 191 faster clearance of PR8. was found in all lobes, the right lung's caval lobe appeared to be commonly more inflamed than 207 other lobes. Pulmonary invagination was often associated with inflamed portions of the lungs.
10
Co-infection with RV induced earlier inflammation, but reduced the severity of 209 inflammation elicited by PR8. By day 4, lung pathology was more extensive in RV/PR8 co-210 infected mice than Mock/PR8-infected mice. However, by days 7 and 10, mice infected with 211 Mock/PR8 had more severe lung pathology than RV/PR8 co-infected mice. Overall, necrosis and 212 desquamation in the trachea, bronchi, bronchioles, and alveoli were more severe in Mock/PR8 213 than in RV/PR8 co-infected mice. Furthermore, excessive mucopurulent material consisting of Co-infection by RV was effective at reducing disease during a mild or moderate PR8 236 infection when given two days before PR8. We next determined whether co-infection with RV 237 simultaneously with or two days after a low or medium dose of PR8 would also ameliorate 238 disease. When RV and PR8 Low were inoculated simultaneously (RV+PR8 Low ), co-infection 239 resulted in a disease phenotype intermediate between PR8 Low alone (Mock/PR8 Low ) and RV two 240 days before PR8 Low (RV/PR8 Low ) ( Fig. 6A-C) . RV+PR8 Low co-infected mice reached 33% 241 mortality by day 9 (Fig. 6A ). This mortality was higher than mice inoculated with RV two days 242 before PR8 Low (RV/PR8 Low ), but significantly lower than the 100% mortality seen with mice 243 infected with PR8 Low alone (Mock/PR8 Low ). RV+PR8 Low -infected mice lost weight at a similar 244 rate to Mock/PR8 Low -infected mice, beginning on day 3 and continuing until day 8 before 245 recovering ( Fig. 6B ). Average clinical scores were also similar between simultaneous co-246 infection and single infection, with slight lethargy, hunching, breathing, and moderate ruffling 247 detected on day 3 and 4 and peaking with moderate lethargy, hunching, breathing, and severe 248 ruffling on day 7 before co-infected mice (RV+PR8 Low ) began recovering from infection ( Fig.   249 6C). Interestingly, when RV was given two days after PR8 Low (PR8 Low /RV), co-infection 250 exacerbated PR8 disease, as evidenced by more rapid mortality, weight loss, and higher clinical 251 scores than mice infected with Mock/PR8 Low (Fig. 6A-C ). PR8 Low /RV co-infected mice began 252 dying and reached 100% mortality two days before mice inoculated with Mock/PR8 Low (Fig. 6B ).
253
PR8 Low /RV co-infected mice also lost weight at a greater rate and had dramatically higher 254 clinical scores than other single virus-and co-infected groups (Fig. 6B, C) . These increased 255 clinical scores were due to severe lethargy and ruffling, moderate hunching, and labored 256 breathing, which occurred earlier during infection compared to mice in the other groups ( Fig.   257 6C).
258
In contrast to PR8 Low , RV was only effective at disease attenuation when given two days 259 before a higher dose (PR8 Med ) of PR8. There were no significant differences in mortality, weight 260 loss, or clinical signs between simultaneously co-infected (RV+PR8 Med ) mice and mice 261 inoculated with PR8 Med alone ( Fig. 6D-F ). Both of these groups steadily lost weight between 262 days 3-8 and reached 100% mortality by day 8 (Fig. 6D , E). RV+PR8 Med co-infected mice had 263 slightly lower clinical scores than Mock/PR8 Med -infected mice (Fig. 6F ), and did not experience 264 severely labored breathing like Mock/PR8 Med -infected mice. However, these differences in 265 clinical signs did not affect mortality. When RV was inoculated two days after PR8 Med 266 (PR8 Med /RV), all mice reached humane endpoints by day 7, one day earlier than mice inoculated 267 with Mock/PR8 Med (Fig. 6D ). PR8 Med /RV co-infected mice lost weight at a similar rate to , 19-22) . Here, we developed a murine model of respiratory viral co-infection to study the 318 effects on disease severity in a system where we can control the virus strains, doses, order, and 319 timing of which they infect the host. We found that mice given RV two days before PR8 were 320 15 completely protected against mortality and had reduced morbidity. RV was less effective at 321 disease attenuation when mice were given higher doses of PR8, or RV was given at the same 322 time as PR8. Further, mice given RV two days after PR8 had enhanced disease compared to PR8 323 alone. We also found that disease attenuation was not limited to co-infection by RV. A 324 respiratory tropic strain of MHV also reduced PR8 disease when given two days before PR8.
325
Unlike RV, MHV caused significant morbidity in mice. However, reducing the dose of MHV to 326 lessen pathogenesis was less effective at reducing the severity of PR8. These data suggest that 327 changes in pathogenesis during co-infection are dependent upon the severity of each infection 328 and the order and timing of inoculation.
329
Despite preventing mortality and significantly inhibiting morbidity, infection of mice 330 with RV two days before PR8 did not reduce PR8 levels in the lungs early in infection (Fig. 2) or 331 prevent spread of PR8 within the respiratory tract (Fig. 3) . These findings suggest that RV does 332 not directly inhibit infection by PR8, which was also confirmed by our in vitro studies (Fig. 4) .
333
Our previous studies have shown that RV induces a robust type I IFN response in the LA-4 cell 334 line (30), thus the lack of PR8 inhibition we saw is not due to the absence of an IFN response.
335
This is not surprising, as the NS1 protein of PR8 is known to antagonize type I IFN responses 
357
Neutrophil levels in the airways of RV-infected mice peak on days 1 and 2 and decline by day 4, 358 while lymphocytes are present through day 7 (27, 32, 33, 36, 37) . Studies differ in whether 359 macrophage numbers change significantly upon RV infection in mice (27, 32, 33, 36) . Type I 360 and III interferons, proinflammatory cytokines, and neutrophil and lymphocyte recruiting 361 chemokines are also up-regulated in response to RV infection in mice (27, 32, 33) . These cellular 362 and cytokine responses are not stimulated by UV-inactivated virus, suggesting that viral 363 replication is required (27, 33) . We observed increased macrophages and lymphocytes and 364 enhanced perivascular cuffing in histology sections from RV/PR8 co-infected animals, 365 suggesting a robust cellular immune response. Ongoing studies in our lab will determine the RV-366 induced immune components that are required for attenuation of PR8 disease during co-infection.
367
In contrast to the enhanced inflammation in the lungs of co-infected mice on day 4, the 368 histopathology on days 7 and 10 was less severe in co-infected compared to PR8-infected mice 369 (Fig. 5 ). This could be an indirect consequence of early viral clearance (Fig. 2) or active down-370 regulation of the inflammatory response in co-infected animals. Multiple studies have shown that 371 inflammation during influenza and other respiratory viral infections can cause pathogenesis that 372 is independent of viral levels in the lungs (34, 35, (38) (39) (40) . Our histopathology data are in 373 agreement with studies that demonstrate excessive inflammatory responses occurring as viral 374 loads are decreasing (23, 41) . We inoculated mice with PR8 two days after RV inoculation, 
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This study demonstrated that RV-mediated disease attenuation was less effective as we 383 increased the dose of PR8, shortened the timing between virus inoculations, or gave RV after 384 PR8 (Figs. 1 and 6 ). These differences are likely due to the kinetics and magnitudes of RV-and 385 PR8-induced immune responses. Higher doses of PR8 likely overwhelm defense mechanisms 386 that are induced by RV and these defense mechanisms are likely not induced quickly enough to 387 completely protect against PR8 given at the same time. However, the observation that RV given 388 two days after PR8 exacerbates pathogenesis suggests that once a response to PR8 has been 389 initiated, the RV-induced response may aggravate immunopathology. RV induces multiple 390 immune components that are known to contribute to influenza disease, including neutrophils (43), 391 NK cells (45), and type I IFNs (46, 47) . Further studies are needed to identify the mechanisms 392 that exacerbate disease when RV is given 2 days after PR8. It is possible that these are the same 393 mechanisms that reduce disease when RV is given 2 days before PR8 and that the timing of their 394 induction is key to regulating pathogenesis.
395
Interestingly, infection by MHV two days prior to PR8 also reduced the severity of PR8 396 infection. Unlike RV, MHV causes morbidity and mortality in mice, though virulence is mouse 397 strain-dependent (28, 29, 48) . We have observed dose-dependent severity of MHV in BALB/c 398 mice. Intranasal inoculation of 2 x 10 3 PFU resulted in clinical disease with low mortality (Fig.   399   7) , while a dose of 2 x 10 5 caused 100% mortality (data not shown). Survival of BALB/c mice 400 upon MHV-1 infection is dependent upon a type I IFN response (49). Furthermore, mouse strain-401 dependent resistance to MHV-1 disease corresponds with robust expression of type I IFNs (28).
402
Based on these studies, we expect that the type I IFN response is adequate to protect BALB/c In vitro co-infection experiments 478 LA-4 cells were inoculated with PR8 (MOI=1) either 6 or 12 h after or simultaneously with 479 inoculation with RV (MOI=1). After 1 h incubation with the inoculum, cells were washed twice 480 with serum-free medium, then incubated in Ham's F12K medium with 2% FBS and antibiotics at 481 37°C. Supernatant media was collected from the cells at 6, 12, 18, 24, 48, 72 , and 96 hours after 482 PR8 inoculation and PR8 was titrated by TCID 50 assay using MDCK cells. 
